Quick Verdict: Intuitive Surgical’s Q1 2026 revenue climbed to $2.77 billion, beating consensus by roughly $150 million, while non‑GAAP EPS jumped to $2.50, well ahead of expectations. Despite the strong print and raised 2026 procedure guidance, the stock fell about 3% in regular trading before recovering modestly after-hours
About Intuitive Surgical, Inc
Intuitive Surgical, Inc. (NASDAQ: ISRG) is a U.S.-based medical technology company that pioneered robotic‑assisted surgery and dominates the market with its da Vinci surgical systems and Ion endoluminal platform. Headquartered in Sunnyvale, California, Intuitive was founded in 1995 and has grown into one of the world’s largest medtech names by market value. As of April 2026, the company’s market capitalization is around $160 billion, placing it among the top global healthcare innovators. Intuitive focuses on minimally invasive procedures across urology, gynecology, general surgery, thoracic and other specialties, combining hardware, software, analytics and services into an integrated ecosystem. The stock trades on a rich valuation with a trailing P/E ratio near the high‑50s to low‑60s, reflecting strong growth expectations and premium pricing versus broader medtech peers. Intuitive employs roughly 17,000 people worldwide and does not currently pay a cash dividend, reinvesting heavily in R&D and commercial expansion.
Top Financial Highlights
- Total revenue rose to $2.77 billion, up 23% year over year from $2.25 billion in Q1 2025, driven by higher procedure volumes and system placements.
- GAAP net income attributable to Intuitive increased to $822 million (diluted EPS $2.28) from $698 million (EPS $1.92) a year earlier.
- Non‑GAAP net income reached $901 million, with non‑GAAP diluted EPS of $2.50, up from $662 million and $1.81 respectively in Q1 2025.
- GAAP gross profit was $1.83 billion, implying a 66.1% gross margin, while non‑GAAP gross profit of $1.88 billion translated to a 67.8% margin, both modestly higher year over year.
- GAAP income from operations rose to $855 million; non‑GAAP income from operations climbed to about $1.08 billion, yielding a strong ~39% non‑GAAP operating margin.
- Instruments and accessories revenue grew 23% to roughly $1.69 billion, reflecting about 16% growth in da Vinci procedure volume and 39% growth in Ion procedures alongside customer buying patterns.
- Systems revenue increased to about $651 million from $523 million, supported by 431 da Vinci system placements (including 232 da Vinci 5 systems) and a larger lease installed base.
- Service revenue rose about 19% to $434 million, buoyed by a 12% increase in the da Vinci installed base and 22% growth in Ion systems.
- Worldwide procedures (da Vinci + Ion) grew approximately 17%, with da Vinci procedures up 16% and Ion procedures up 39%, highlighting robust adoption across platforms.
- Intuitive expanded its installed base to 11,395 da Vinci systems (up 12% YoY) and 1,041 Ion systems (up 22% YoY) as of March 31, 2026.
- The company ended the quarter with $7.98 billion in cash, cash equivalents and investments, down $1.05 billion sequentially, mainly due to $1.1 billion of share repurchases and a business acquisition.
- Intuitive repurchased 2.3 million shares during Q1 2026, reinforcing ongoing capital‑return commitments while maintaining a sizable cash buffer.
- For full‑year 2026, management guides to 13.5%–15.5% da Vinci procedure growth, non‑GAAP gross margin of 67.5%–68.5% (including about 100 bps of tariff drag), and non‑GAAP operating expense growth of 11%–14%.
Beat or Miss?
| Metric | Reported Q1 2026 | Difference / Analysis |
| Revenue | $2.77 billion | Beat Street consensus of roughly $2.61–$2.62 billion by about $0.15 billion (~6% upside). |
| Non‑GAAP EPS | $2.50 | Topped consensus near $2.08–$2.12 by roughly $0.40, delivering ~18–20% EPS surprise. |
| GAAP Diluted EPS | $2.28 | No widely cited GAAP EPS consensus; result comfortably above last year’s $1.92 baseline. |
| Total Procedure Growth | +17% YoY | Outpaced many medtech peers; compares favorably with long‑term mid‑teens growth expectations. |
| Non‑GAAP Operating Margin | ~39% | Strong leverage versus prior‑year margin in the high‑30s, despite ongoing tariff and input‑cost headwinds. |
What Leadership Is Saying
We are pleased with company performance this quarter, which was marked by expanded adoption of our da Vinci, Ion, and digital platforms.
We are pleased with our financial performance and remain focused on delivering sustainable growth and value to our shareholders.
The first quote, from CEO Dave Rosa, underscores Intuitive’s strategy of broadening adoption across its multi‑platform robotic and digital ecosystem rather than relying on a single flagship system. The second, attributed to the company’s CFO in a transcript summary, highlights management’s emphasis on maintaining strong profitability and disciplined capital allocation alongside growth.
Historical Performance (YoY – Intuitive Surgical)
Intuitive’s Q1 2026 results represent a continuation – and acceleration – of the company’s multi‑year growth trajectory, with revenue, earnings and margins all improving versus the prior‑year quarter. Operating expenses are rising in absolute terms as Intuitive invests in R&D, digital capabilities and international expansion, but margins remain robust due to scale and mix.
| Category | Q1 2026 (ended Mar 31) | Q1 2025 (ended Mar 31) | Change (%) |
| Revenue | $2.77 billion | $2.25 billion | +23% (company‑reported) |
| GAAP Net Income | $821.5 million | $698.4 million | ~+18% (approx. from reported figures) |
| Total Operating Expenses | $975.2 million | $879.6 million | ~+11% (approx. from reported figures) |
These year‑over‑year gains reflect higher recurring revenue from instruments, accessories and services, plus expanding scale for newer platforms such as Ion and da Vinci 5. Non‑GAAP operating income and EPS grew even faster than GAAP metrics, as stock‑based compensation, amortization and other adjustments remained relatively stable.
Historical Performance
For competitive context, Stryker Corporation (NYSE: SYK), a major medtech peer with its Mako robotic orthopedic platform, reported strong calendar Q4 2025 results – its latest disclosed quarter – versus Q4 2024. While not directly comparable in timing or mix, the figures illustrate how another large surgical‑robotics player is trending on growth and profitability.
| Category | Stryker Q4 2025 (CY) | Stryker Q4 2024 (CY, approx.) | Change (%) |
| Revenue | $7.17 billiontradingview | ≈**$6.44 billion** (implied from 11.4% YoY growth)tradingview | +11.4% reported revenue growthtradingview |
| Adjusted EPS | $4.47finance.yahoo | ≈**$4.01** (implied from 11.5% YoY growth)finance.yahoo | +11.5% adjusted EPS growthfinance.yahoo |
| Adjusted Operating Margin | 30.2%finance.yahoo | 29.2% (about 100 bps lower)finance.yahoo | ~+100 bps margin expansionfinance.yahoo |
Stryker’s double‑digit organic sales growth and margin expansion, supported by record Mako installations, mirror Intuitive’s own combination of high‑teens procedure growth and rising profitability. Prior‑year Stryker figures in the table are inferred from reported growth rates and may differ slightly from disclosed numbers due to rounding, but they still illustrate a robust competitive backdrop for premium surgical‑robotics franchises.
How the Market Reacted?
Despite beating expectations on both revenue and EPS, Intuitive’s shares fell about 3.1% in regular trading on April 21, 2026, closing near $465.60 as investors digested the outlook and regional headwinds. The stock then rebounded roughly 0.7% after hours to around $468.74, suggesting some buyers stepped in once the initial reaction to guidance and commentary was absorbed. Commentary highlighted strong adoption of da Vinci 5 and Ion but also pointed to ongoing pressures in Asian hospital markets and a more modest 2026 procedure‑growth range, which may have tempered enthusiasm given the stock’s premium valuation. Overall, the reaction looks like a “beat‑but‑not‑enough” response: fundamentals remain solidly bullish, yet expectations and valuation leave little room for disappointment.